Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

In the CARTITUTE-4 trial, the EMD subgroup analysis demonstrated a median PFS of 13 months versus 4 months for cilta-cel versus standard of care (HR 0.71; 95% CI, 0.34–1.49) [ 8 ], suggesting a trend toward benefit that did not reach statistical significance in this limited subgroup.

also in 111,027 other papers